Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21.

Article  PubMed  Google Scholar 

Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreira M, Pobel C, Epaillard N, Simonaggio A, Oudard S, Vano YA. Resistance to cancer immunotherapy in metastatic renal cell carcinoma. Cancer Drug Resist. 2020;3(3):454–471.

Martin SD, Bhuiyan I, Soleimani M, Wang G. Biomarkers for immune checkpoint inhibitors in renal cell carcinoma. J Clin Med. 2023;12(15).

Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116.

Article  PubMed  PubMed Central  Google Scholar 

Hong S, Yuan Q, Xia H, Dou Y, Sun T, Xie T, et al. Establishment of an ex vivo tissue culture model for evaluation of antitumor efficacy in clear cell renal cell carcinoma. Front Oncol. 2022;12:851191.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lasorsa F, di Meo NA, Rutigliano M, Milella M, Ferro M, Pandolfo SD et al. Immune checkpoint inhibitors in renal cell carcinoma: molecular basis and rationale for their use in clinical practice. Biomedicines. 2023;11(4).

Seeber A, Klinglmair G, Fritz J, Steinkohl F, Zimmer K-C, Aigner F, et al. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. Cancer Sci. 2018;109(5):1583–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin C-C, Garralda E, Schöffski P, Hong DS, Siu LL, Martin M, et al. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. Oncoimmunology. 2024;13(1):2290787.

Article  PubMed  Google Scholar 

Jacob S, Daud A. Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease. JCO. 2023;41(16suppl):TPS9595–9595.

Article  Google Scholar 

Luo L, Zhu G, Xu H, Yao S, Zhou G, Zhu Y, et al. B7-H3 promotes pathogenesis of Autoimmune Disease and inflammation by regulating the activity of different T cell subsets. PLoS ONE. 2015;10(6):e0130126.

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Fraser CC, Kikly K, Wells AD, Han R, Coyle AJ, et al. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol. 2005;35(2):428–38.

Article  CAS  PubMed  Google Scholar 

Prasad DVR, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173(4):2500–6.

Article  CAS  PubMed  Google Scholar 

Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, et al. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol. 2020;17(3):227–36.

Article  CAS  PubMed  Google Scholar 

Iida K, Miyake M, Onishi K, Hori S, Morizawa Y, Gotoh D, et al. Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. Oncol Lett. 2019;17(4):4004–10.

CAS  PubMed  PubMed Central  Google Scholar 

Jin Y, Zhang P, Li J, Zhao J, Liu C, Yang F, et al. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(11):13987–95.

CAS  PubMed  PubMed Central  Google Scholar 

Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, et al. B7-H3 negatively modulates CTL-Mediated Cancer Immunity. Clin Cancer Res. 2018;24(11):2653–64.

Article  CAS  PubMed  Google Scholar 

Zhang X, Fang C, Zhang G, Jiang F, Wang L, Hou J. Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis. Oncotarget. 2017;8(54):93156–67.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Article  CAS  PubMed  Google Scholar 

Inamura K, Takazawa Y, Inoue Y, Yokouchi Y, Kobayashi M, Saiura A et al. Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer. J Clin Med. 2018;7(7).

Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, et al. Combination therapy in renal cell carcinoma: the best choice for every patient? Curr Oncol Rep. 2021;23(12):147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Getu AA, Tigabu A, Zhou M, Lu J, Fodstad Ø, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269–74.

Article  CAS  PubMed  Google Scholar 

Saeednejad Zanjani L, Madjd Z, Axcrona U, Abolhasani M, Rasti A, Asgari M, et al. Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma. Ann Diagn Pathol. 2020;46:151483.

Article  PubMed  Google Scholar 

Linehan WM, Srinivasan R, Garcia JA. Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol. 2013;40(4):511–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lichtensztajn DY, Hofer BM, Leppert JT, Brooks JD, Chung BI, Shah SA, et al. Associations of Renal Cell Carcinoma Subtype with patient demographics, comorbidities, and Neighborhood Socioeconomic Status in the California Population. Cancer Epidemiol Biomarkers Prev. 2023;32(2):202–7.

Article  PubMed  PubMed Central  Google Scholar 

Mancini M, Righetto M, Baggio G. Gender-related Approach to kidney Cancer Management: moving Forward. Int J Mol Sci. 2020;21(9).

Scelo G, Li P, Chanudet E, Muller DC. Variability of sex disparities in Cancer incidence over 30 years: the striking case of kidney Cancer. Eur Urol Focus. 2018;4(4):586–90.

Article  PubMed  Google Scholar 

Demasure S, Spriet I, Debruyne PR, Laenen A, Wynendaele W, Baldewijns M, et al. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol. 2022;61(1):22–9.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yekedüz E, Ertürk İ, Tural D, Karadurmuş N, Karakaya S, Hızal M, et al. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future Oncol. 2021;17(35):4861–9.

Article  PubMed  Google Scholar 

Verhaart SL, Abu-Ghanem Y, Mulder SF, Oosting S, Van Der Veldt A, Osanto S et al. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. Clin Genitourin Cancer. 2021;19(3):274.e1-274.e16.

Obinata D, Funakoshi D, Sakurai F, Yoshizawa T, Mochida J, Yamaguchi K, et al. Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy. Med (Baltim). 2022;101(32):e29510.

Article  CAS  Google Scholar 

Evans ST, Jani Y, Jansen CS, Yildirim A, Kalemoglu E, Bilen MA. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biol Ther. 2024;25(1):2342599.

Article  PubMed  PubMed Central  Google Scholar 

Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14(16):5150–7.

Article  CAS  PubMed